How can small firms benefit from open innovation? the case of new drug development in Taiwan

Yu Shan Su*, Hsin Yi Hu, Feng Shang Wu

*此作品的通信作者

研究成果: 雜誌貢獻期刊論文同行評審

4 引文 斯高帕斯(Scopus)

摘要

How can small firms manage and benefit from open innovation? We study three Taiwan's biotechnology firms leveraging open innovation in developing new drugs. At the phase of the new drug discovery, two companies acquired technology from external sources. CSRC Synpac Company acquired technology from Professor Yuan-Tsong Chen at Duke University (USA) in 1991. GlycoNex Company acquired technology from Professor Sen-itiroh Hakomori at University of Washington (USA) in 2001. AbGenomics Company developed its own technology at Professor Rong-Hwa Lin's team at National Taiwan University (Taiwan) in 2000. Through technology transfer, CSRC Synpac Company licensed out the new drug Myozyme to Genzyme Corporation (USA) in 2000. AbGenomics Company licensed out the new drug AbGn-168H to Boehringer Ingelheim Pharmaceutical (Germany) in 2005. GlycoNex Company licensed out the new drug GNX-8 to Otsuka Pharmaceutical (Japan) in 2009.

原文英語
頁(從 - 到)61-82
頁數22
期刊International Journal of Technology Management
72
發行號1
DOIs
出版狀態已發佈 - 2016

ASJC Scopus subject areas

  • 勞資關係
  • 一般工程
  • 電腦科學應用
  • 策略與管理
  • 法律

指紋

深入研究「How can small firms benefit from open innovation? the case of new drug development in Taiwan」主題。共同形成了獨特的指紋。

引用此